R. Siegel, D. Naishadham, and A. Jemal, Cancer statistics, 2013, CA: A Cancer Journal for Clinicians, vol.287, issue.suppl 5, pp.11-30, 2013.
DOI : 10.3322/caac.21166

D. Hanahan and R. Weinberg, Hallmarks of Cancer: The Next Generation, Cell, vol.144, issue.5, pp.646-74, 2011.
DOI : 10.1016/j.cell.2011.02.013

T. Lynch, D. Bell, and R. Sordella, Activating Mutations in the Epidermal Growth Factor Receptor Underlying Responsiveness of Non???Small-Cell Lung Cancer to Gefitinib, New England Journal of Medicine, vol.350, issue.21, pp.2129-2168, 2004.
DOI : 10.1056/NEJMoa040938

A. Shaw, D. Kim, and K. Nakagawa, -Positive Lung Cancer, New England Journal of Medicine, vol.368, issue.25, pp.2385-94, 2013.
DOI : 10.1056/NEJMoa1214886

URL : https://hal.archives-ouvertes.fr/in2p3-00451031

L. Alexandrov, S. Nik-zainal, and D. Wedge, Signatures of mutational processes in human cancer, Nature, vol.27, issue.7463, pp.415-436, 2013.
DOI : 10.1038/nature12477

D. Planchard, J. Mazieres, and G. Riely, Interim results of phase II study BRF113928 of dabrafenib in braf V600E mutation?positive non-small cell lung cancer (NSCLC) patients

J. Mazières, S. Peters, and B. Lepage, Mutation: Epidemiologic Characteristics and Therapeutic Perspectives, Journal of Clinical Oncology, vol.31, issue.16, pp.1997-2003, 2013.
DOI : 10.1200/JCO.2012.45.6095

D. Camidge, S. Ou, and G. Shapiro, Efficacy and safety of crizotinib in patients with advanced c-MET-amplified non-small cell lung cancer (NSCLC), ):5s; [Abstr:8001)], 2014.

M. Kris, B. Johnson, and L. Berry, Using Multiplexed Assays of Oncogenic Drivers in Lung Cancers to Select Targeted Drugs, JAMA, vol.311, issue.19, pp.1998-2006, 2014.
DOI : 10.1001/jama.2014.3741

M. Serizawa, Y. Koh, and H. Kenmotsu, Assessment of mutational profile of Japanese lung adenocarcinoma patients by multitarget assays: A prospective, single-institute study, Cancer, vol.81, issue.suppl, pp.1471-81, 2014.
DOI : 10.1002/cncr.28604

L. Sequist, R. Heist, and A. Shaw, Implementing multiplexed genotyping of non-small-cell lung cancers into routine clinical practice, Annals of Oncology, vol.22, issue.12, pp.2616-2640, 2011.
DOI : 10.1093/annonc/mdr489

Z. Su, D. Dias-santagata, and M. Duke, A Platform for Rapid Detection of Multiple Oncogenic Mutations With Relevance to Targeted Therapy in Non???Small-Cell Lung Cancer, The Journal of Molecular Diagnostics, vol.13, issue.1, pp.74-84, 2011.
DOI : 10.1016/j.jmoldx.2010.11.010

F. Andre, F. Nowak, M. Arnedos, L. Lacroix, P. Viens et al., Biomarker Discovery, Development, and Implementation in France: A Report from the French National Cancer Institute and Cooperative Groups, Clinical Cancer Research, vol.18, issue.6, pp.1555-60, 2012.
DOI : 10.1158/1078-0432.CCR-11-2201

F. Nowak, J. Soria, and F. Calvo, Tumour molecular profiling for deciding therapy???the French initiative, Nature Reviews Clinical Oncology, vol.456, issue.8, pp.479-86, 2012.
DOI : 10.1038/nrclinonc.2012.42

F. Nowak, F. Calvo, and J. Soria, Europe Does It Better: Molecular Testing across a National Health Care System???The French Example, American Society of Clinical Oncology Educational Book, vol.33, pp.332-339
DOI : 10.1200/EdBook_AM.2013.33.332